Strong Clinical Momentum for Soligenix's HyBryte(TM) in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte(TM)- Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Expanded HyBryte(TM) Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.